A Form 4 filed on August 13, 2026, disclosed that Adam R. Craig, Executive Chairman and Director of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), sold 47,436 shares of common stock on August 12, 2026, to cover personal income tax obligations arising from the settlement of a restricted stock unit award.

Key Highlights

  • Reporting person: Adam R. Craig, Executive Chairman and Director of X4 Pharmaceuticals, Inc.
  • Shares sold: 47,436 shares of common stock disposed of on August 12, 2026.
  • Weighted average price: $4.4445 per share, with individual transactions ranging from $4.33 to $4.55, inclusive.
  • Purpose of sale: Shares were sold to cover a personal income tax obligation upon settlement of a restricted stock unit award.
  • Remaining beneficial ownership: 328,651 shares of common stock held directly following the transaction.
  • RSU component: Of the 328,651 shares reported, 193,254 represent restricted stock units.

Craig's RSU Tax Sale Details at X4 Pharmaceuticals

According to the filing, Adam R. Craig, serving as Executive Chairman and Director of X4 Pharmaceuticals, Inc., disposed of 47,436 shares of common stock on August 12, 2026. The filing identifies the transaction code as "S" and categorizes the shares as disposed of (D). The stated reason for the sale, as noted in the filing's explanation of responses, is a "sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."

The filing reports that the price of $4.4445 per share is a weighted average across multiple transactions. Individual sales occurred at prices ranging from $4.33 to $4.55, inclusive. The filing states that Craig, through attorney-in-fact David Kirske, undertakes to provide the issuer, any security holder, or SEC staff with full information on the number of shares sold at each separate price within that range, upon request.

Following the reported transaction, Craig's direct beneficial ownership stands at 328,651 shares of common stock. The filing notes that of those shares, 193,254 represent restricted stock units. The Form 4 was filed by one reporting person and is not identified as an amendment to a prior filing.

What Was Disclosed

The filing disclosed a sale of 47,436 common shares by X4 Pharmaceuticals' Executive Chairman on August 12, 2026, at a weighted average price of $4.4445, conducted to satisfy a personal tax obligation connected to an RSU settlement, leaving 328,651 shares of direct beneficial ownership.